Literature DB >> 15827436

Pathogenesis of hepatocellular carcinoma.

Darius Moradpour1, Hubert E Blum.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumours worldwide. The major aetiologies and risk factors for the development of HCC are well defined and some of the multiple steps involved in hepatocarcinogenesis have been elucidated in recent years. However, no clear picture of how and in what sequence these factors interact at the molecular level has emerged yet. Malignant transformation of hepatocytes may occur as a consequence of various aetiologies, such as chronic viral hepatitis, alcohol, and metabolic disorders, in the context of increased cellular turnover induced by chronic liver injury, regeneration and cirrhosis. Activation of cellular oncogenes, inactivation of tumour suppressor genes, genomic instability, including DNA mismatch repair defects and impaired chromosomal segregation, overexpression of growth and angiogenic factors, and telomerase activation may contribute to the development of HCC. Overall, HCCs are genetically very heterogeneous tumours. New technologies, including gene expression profiling and proteomic analyses, should allow us to further elucidate the molecular events underlying HCC development and identify novel diagnostic markers as well as therapeutic targets.

Entities:  

Mesh:

Year:  2005        PMID: 15827436     DOI: 10.1097/00042737-200505000-00002

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  42 in total

1.  The mitochondrial DNA 9-bp deletion polymorphism is a risk factor for hepatocellular carcinoma in the Chinese population.

Authors:  Yiqi Jin; Qiang Yu; Dayong Zhou; Lei Chen; Xianchen Huang; Guoxiong Xu; Jian Huang; Xueren Gao; Yuzhen Gao; Liming Shen
Journal:  Genet Test Mol Biomarkers       Date:  2012-01-27

2.  Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States.

Authors:  Jon D Dorfman; Richard Schulick; Michael A Choti; Jean-Francois H Geschwind; Ihab Kamel; Michael Torbenson; Paul J Thuluvath
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

3.  Current imaging strategies of primary and secondary neoplasms of the liver.

Authors:  Linda Fielding
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

Review 4.  Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

Authors:  Pavan Patel; Steven E Schutzer; Nikolaos Pyrsopoulos
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

Review 5.  Epigenetic aspects of genotoxic and non-genotoxic hepatocarcinogenesis: studies in rodents.

Authors:  Igor P Pogribny; Ivan Rusyn; Frederick A Beland
Journal:  Environ Mol Mutagen       Date:  2008-01       Impact factor: 3.216

Review 6.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

7.  Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Marialina Tornesello; Maria Napolitano; Debora Martorelli; Giuseppe Castello; Gerardo Beneduce; Amalia De Renzo; Oreste Perrella; Luca Romagnoli; Vitor Sousa; Valli De Re; Riccardo Dolcetti; Franco M Buonaguro
Journal:  J Transl Med       Date:  2010-02-19       Impact factor: 5.531

8.  Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase.

Authors:  Nikolaos Stefanou; Vassilis Papanikolaou; Yoichi Furukawa; Yusuke Nakamura; Aspasia Tsezou
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

9.  Aflatoxin B(1)-Associated DNA Adducts Stall S Phase and Stimulate Rad51 foci in Saccharomyces cerevisiae.

Authors:  Michael Fasullo; Yifan Chen; William Bortcosh; Minzeng Sun; Patricia A Egner
Journal:  J Nucleic Acids       Date:  2010-12-02

10.  Predominant modifier of extreme liver cancer susceptibility in C57BR/cdJ female mice localized to 6 Mb on chromosome 17.

Authors:  Stephanie E-M Peychal; Andrea Bilger; Henry C Pitot; Norman R Drinkwater
Journal:  Carcinogenesis       Date:  2009-03-02       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.